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Objectives: To improve conventional chemotherapeutic efficacy, it is 
important to detect new molecular markers for chemosensitivity as well 
as possible accelerating cell killing mechanism. In this study, we 
investigated how MK2206, an allosteric Akt inhibitor, enhances the 
cisplatin (CDDP)-induced cytotoxicity and apoptosis in urothelial cancer 
cells.  
Materials and methods: We examined bladder cancer cell lines for the  
expression of phospho-Akt and its downstream targets by Western blot. 
The potential antitumor effects were analyzed by MTT assay in vitro and  
by subcutaneous xenograft models in vivo. The cell invasion was 
examined by transwell invasion assay, and the activities of Akt signaling 
pathway and expression of apoptosis-related proteins were measured by 
Western blot.  
Results: The expression of phospho-Akt and its downstream targets was 
increased in invasive bladder cancer cell lines vs in noninvasive bladder 
cancer cell lines. MK2206 (500 nM) inhibited cell invasion in UMUC3 
cell line and significantly increased the susceptibility of bladder cancer 
cell lines to CDDP. When used in combination with CDDP, MK2206 
(500 nM) enhanced CDDP-induced cytotoxicity and apoptosis, with 
suppressed expression of p-Akt and its downstream targets. In vivo 
MK2206 combined with CDDP effectively suppressed tumor growth in 
subcutaneous xenograft models. 
Conclusions: These results suggest that concomitant use of MK2206 
could promote the CDDP-induced cytotoxicity and apoptosis in urothelial 
cancer cell lines through the inhibited expression of Akt pathway. This 
combined treatment may provide a new therapeutic option to enhance 
chemosensitivity in bladder cancer. 
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1. Introduction 
Urothelial cancers are common malignancies and considerable causes 
of morbidity and mortality. Muscle-invasive bladder urothelial cancers 
are difficult to control by less-invasive transurethral resection and often 
require radical cystectomy [1]. Even after complete removal, the patient 
prognosis is poor because of frequent metastatic recurrence. Cisplatin 
(CDDP)-based chemotherapy has been adopted for these advanced or 
recurrent urothelial cancers, although the use of chemotherapy is 
associated with significant toxicity and provides long-term survival in 
only 15-20% of patients due to innate or acquired resistance to 
chemotherapy. To improve chemotherapeutic efficacy and explore the 
molecular mechanisms, it is important to detect novel molecular markers 
for chemosensitivity and identify possible target-associated cell-killing 
mechanisms in urothelial cancer cells. 
  Akt is a serine-threonine kinase activated by growth factors or survival 
factors to regulate cell growth, survival, proliferation and metabolism 
[2-4]. The Phosphatidylinositol-3 kinase (PI3K)/Akt pathway plays a key 
role in survival when cancer cells are exposed to different kinds of 
apoptotic stimuli, such as the withdrawal of extracellular signaling factors, 
oxidative and osmotic stress, irradiation, matrix adhesion, ischemic shock 
and chemotherapeutic drugs [5-8]. Recent evidence indicates that Akt is 
frequently constitutively activated in many types of human cancer, and 
activated Akt signaling is a significant contributor to tumor progression 
and poor prognosis, including bladder cancer [9-11]. Moreover, Akt 
overexpression is often associated with resistance to chemotherapy or 
radiotherapy [12,13]. Dominant-negative mutants of Akt enhance the 
cytotoxicity of chemotherapeutic agents, suggesting an important role of 
Akt in drug resistance [14]. Some studies have shown that Akt activation 
seems to be related to CDDP resistance of ovarian cancer cells and lung 
cancer cells [15,16]. Thus, chemotherapeutic agents that could be 
sensitized by Akt inhibition is highly desirable to guide the clinical 
application of Akt inhibitors. 
  MK2206 is a highly potent and selective allosteric Akt inhibitor that is 
under development for the treatment of solid tumors. Previous reports 
have demonstrated that MK2206 has antitumor activity alone and 
enhanced antitumor efficacy in combination with chemotherapeutic 
agents in solid tumors [17-21]. In the present study, we demonstrated that 
the effectiveness of MK2206 to enhance CDDP-induced cytotoxicity and 
apoptosis, through the inhibition of phospho-Akt expression and its 
downstream targets. This study may provide useful information to 
develop a potential new therapeutic approach for bladder cancer by 
targeting the Akt pathway to increase CDDP sensitivity.   
 
2. Materials and methods 
2.1 Antibodies and reagents 
Antibodies were obtained as follows: anti-Akt, phospho-Akt (ser473), 
phospho-Akt (Thr308), phospho-4EBP1, phospho-mTOR, phospho-S6RP, 
phospho-70S6K, phospho-GSK3β, anti-mTOR, bax, survivin (71G4B7),  
cleaved caspase-3, Ki-67, Snail, Slug and TCF8/ZEB1 from Cell 
Signaling Technology (Bevery, MA). Anti-caspase-8, anti-caspase-9 from 
BD Pharmingen (San Diego, CA). MK2206 was obtained from Active 
Biochem (Maplewood, NJ) and CDDP was from WAKO (Osaka, Japan). 
2.2 Cell culture 
Six bladder cancer cell lines (RT112, RT4, 253J, J82, T24, UMUC3) 
were maintained in RPMI1640 medium supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin. Cells were incubated at 
37°C in a humidified atmosphere containing 5% CO2.  
2.3 MTT assay 
Cell viability was assessed by MTT assay. Briefly, 1×104 cancer cells 
with 100 µl suspension were grown in each well of 96-well plates. After 
24h of incubation, cells were treated with or without different 
concentrations of drugs for another 24h. Then, 20 µl MTT working 
solution (5 mg/ml; Sigma) was added to each culture well and incubated 
for 4h. The absorbance (A) of each well was measured by a microculture 
plate reader (Immunoreader, Japan Intermed Co., Ltd., Tokyo, Japan) at 
540 nm. The percentage of cell viability = ( A of experimental wells / A of 
control wells)×100. These experiments were performed at least three 
times independently. 
2.4 Drug treatment and preparation of cellular extracts 
For the dose-response and the time-course studies, cells were grown to 
70-80% confluency in 100mm dishes for 48h. Then cells were treated 
with CDDP at the corresponding concentrations of IC30. For analysis of 
Akt pathway, cells were treated with CDDP at the concentration 
corresponding to IC30 with or without treatment of 500 nM MK2206.  
After treatment, cells were washed with phosphate-buffered saline (PBS) 
and lysed in an appropriate volume of ice-cold cell lysis buffer (20 mM 
Tris, PH 7.4, 150 mM NaCl, 1 mM EDTA, 1mM EGTA, 1% Triton, 2.5 
mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 
1 µg/ml leupeptin) supplemented with 1 mM phenyl-methylsulfonyl 
fluoride. Cellular lysates were clarified by centrifugation at 15000×g for 
20 min, and the protein concentrations of the lysates were determined by 
a detergent-compatible protein assay kit (Bio-Rad, Hercules, CA). 
Portions of the same cellular extracts were used for Western blot analysis. 
2.5 Western blot analysis 
Thirty to fifty micrograms of protein lysates were separated by 
SDS-PAGE on a 10-15% Tris-HCL minigel, and transferred onto a PVDF 
membrane following standard methods. After blocking, membranes were 
probed with appropriate dilutions of primary antibodies overnight, 
followed by incubation with horseradish peroxidase-conjugated 
secondary antibodies 1h. Proteins were visualized by the 
chemiluminescent detection system. 
2.6 Transwell invasion assay 
For transwell invasion assays, cells were suspended in serum-free 
RPMI 1640. The cell suspensions UMUC3 (5×104) were then added to 
the 8.0 µm pore polyethylene terephthalate filter insert of a 24-well 
transwell cell culture chamber (BD Falcon, Franklin Lakes, NJ, USA) 
and were incubated for 24h with medium containing 10% FBS in the 
bottom of the chamber. Residual cells on the upper side of chambers were 
removed by scraping with cotton swabs and the cells that attached to the 
lower side of the membrane were fixed with 70% ethanol and stained 
with hematoxylin. The number of invaded cells was counted in 3 
randomly selected fields (×200) under microscope. Each experiment was 
triplicated and performed three times independently. 
2.7 Mouse xenograft model 
To produce a subcutaneous xenograft model, 5×106 RT112 cells in 100 
µl phosphate buffered saline were inoculated subcutaneously into each 
flank of pathogen-free 5-week-old female BALB/cAJcl-nu/nu mice 
(Nihon Clea, Japan). After growing for 7 days, mice with tumor xenograft 
were divided into four groups (5 mice each group) and treated for 2 
weeks as follows: (a) vehicle alone (DMSO); (b) CDDP at 6 mg/kg 
weekly; (c) MK2206 at 50 mg/kg weekly; (d) combination of (b) and (c). 
We administered CDDP or MK2206 by intraperitoneal injection. The 
doses and injection regimens for these drugs were based on reports 
published previously [19,22]. Mice body weight and tumor size were 
measured every other day. Tumor volume was calculated using the 
equation, volume=width2 ×length/2. All mice were sacrificed on day 15 
after initial treatment. Tumors were excised and formalin fixed for Ki-67  
immunostaining. Approval for these studies was obtained from the 
Animal Research Committee of Graduate School of Medicine, Kyoto 
University. 
2.8 Statistical analysis 
Statistical data was analyzed using Statistical Package for Social 
Sciences (SPSS, version 17.0) software. All data used were representative 
of at least three independent experiments. Quantitative data were 
expressed as mean ± S.D. Comparisons were carried out by the 
Mann-Whitney U test and Kruskal-Wallis test. P values <0.05 were 
considered statistically significant. 
 
3. Results 
3.1 Expression status of Akt signaling pathway in urothelial cancer 
cell lines 
The expression status of phospho-Akt and its downstream targets were 
examined using six urothelial cancer cell lines (RT112, RT4, 253J, J82, 
T24, UMUC3). Invasive cell lines had overexpression of p-Akt (Ser473), 
p-Akt (Thr308) and downstream targets, including p-4EBP1, p-GSK3β, 
p-mTOR, p-70S6K and p-S6RP (Fig. 1). There were no or weak 
expressions of Akt signaling in noninvasive cell lines, RT112 and RT4. 
However, RT112 had the activation of p-70S6K and p-S6RP. 
3.2 The impact of MK2206 on phospho-Akt expression, cell 
proliferation, cell invasion in urothelial cancer cell lines 
To analyze the effects of MK2206 on phospho-Akt expression, the four 
invasive cell lines were treated with increasing doses of MK2206 for 24 
hours. Dose-dependent decreases in the p-Akt (Ser473) expression were 
shown in these cell lines (Fig. 2A). The effects of MK2206 on cell 
proliferation were investigated by MTT assay, corresponding to the same 
concentrations of WB (Fig. 2B). The cell viability rates after 500nM 
MK2206 exposure were 84.24±2.29, 84.34±1.64, 82.52±2.31, 80.88±1.98, 
81.92±2.12% in RT112, 253J, UMUC3, T24 and J82, respectively. In this 
study, we used the concentration (500 nM) at which MK2206 alone 
successfully suppressed p-Akt, but suppressed cell proliferation only 
modestly and did not induce apoptosis (Fig. 2B, Fig 4B-C).  
In order to determine whether MK2206 had any effect on cell invasion, 
we performed Matrigel invasion chamber assay. UMUC3 was treated 
with control (DMSO) or MK2206 (500 nM) and incubated 24h before the 
invasion assay was taken. Invasion capability of UMUC3 treated with 
MK2206 was repressed significantly compared with control group (Fig. 
2C, D). The invasion assay result was influenced by decreased cell 
proliferation because cell proliferation was suppressed about 20% by 
MK2206 at 500nM which could inhibit cell invasion rate around 50% in 
UMUC3 cells (Fig. 2B, D). If normalized, the decrease in cell invasion 
would be roughly 30%. To clarify the functional relevance of molecules 
which were associated with tumor invasion or migration, the expression 
of Snail, Slug and ZEB1 were examined using Western Blot after 
MK2206 treatment. Repression of Snail, Slug and ZEB1 were shown 
when cells were treated with MK2206 for 24h (Fig. 2E). Meanwhile, Akt 
phosphorylation expression was also decreased when exposed to 
MK2206 (500 nM) for 24h in UMUC3 (Fig. 2A). We also tried invasion 
assay in T24, and the observation that MK2206 effect on invasion on the 
T24 invasive cell line is similar with UMUC3. These data may indicate 
that the decreased expression of Akt phosphorylation was associated with 
tumor invasion inhibition through suppression of Snail, Slug and ZEB1. 
3.3 Sensitivity to CDDP in urothelial cancer cell lines and MK2206 
enhanced CDDP-induced cytotoxicity 
The sensitivity to CDDP differed among cells: IC50 monitored by 
MTT assay were 62.6±2.4, 106.7±7.2, 122.1±12.7, 355.4±5.6, 
404.3±14.0 and 695.2±123.1 µM in RT4, RT112, 253J, UMUC3, J82 and 
T24, respectively (Fig. 3A). Combination with 500 nM MK2206 
significantly enhanced sensitivity to CDDP dose-dependently. Significant 
differences in growth rates were observed and statistical differences 
between CDDP and CDDP+MK2206 were p=0.004, p=0.01, p=0.028, 
p=0.028 in RT112, 253J, UMUC3 and T24, respectively (Fig. 3B).  
3.4 Involvement of suppression of Akt pathway in MK2206-mediated  
enhancement of CDDP-induced apoptosis  
To investigate the molecular mechanisms underlying the effects of 
MK2206 in CDDP-induced apoptosis, the p-Akt, p-mTOR, p-4EBP1, 
survivin, Bax, and caspases were examined after MK2206, CDDP and 
CDDP+MK2206 treatment in a time-dependent manner in T24 (Fig. 
4A.1-2). Western blot analysis showed that MK2206 (500nM) alone 
could inhibit the p-Akt expression, but could not induce cleaved forms of 
apoptosis targets (caspases-8/caspase-9/caspase-3) in the time course (Fig. 
4A.1). Concomitant use of CDDP (300 µM) and MK2206 (500 nM) did 
not change the expression of Akt, but it suppressed phosphorylation of 
Akt, 4EBP1 from 3h and phosphorylation of mTOR from 9h. The 
activation of caspase-8/caspase-9/caspase-3, as shown by an increase in 
their cleaved products, occurred from 9h after CDDP plus MK2206 
exposure, but CDDP itself caused slight cleaved forms of 
caspase-8/caspase-3 only in 12h, with no significant change in 
phosphorylation of Akt, 4EBP1, and mTOR. The downregulation of 
survivin, as an anti-apoptotic protein, was observed in 12h after CDDP 
combined with MK2206 treatment (Fig. 4A.2).  
To further assess the effects of Akt pathway on the CDDP-induced 
apoptosis, Western blot was performed using T24 and RT112 cells, which 
were incubated 12h with indicated reagents (Fig. 4B, C). Single treatment 
with CDDP (300 µM) slightly induced cleaved forms of caspase-8 / 
caspase-3, and did not increase the expression of p-Akt, Akt, p-4EBP1 
and p-mTOR significantly in T24 (Fig. 4B). On the other hand, the 
cleaved products of caspase-8/caspase-9/caspase-3 were observed in 
RT112 with the single treatment of CDDP. Interestingly, compared with 
T24, in which there was no obvious change in the expression of Akt 
signaling through CDDP exposure, significant increase in its expression 
after CDDP (50 µM) exposure was identified in RT112 (Fig. 4C). 
MK2206 and CDDP induced significant suppression of p-Akt, p-4EBP1, 
p-mTOR, survivin and activated caspases in both cell lines, in contrast to 
MK2206 or CDDP single treatment. These findings suggested that 
suppression of Akt pathway played an important role in the enhancement 
of CDDP-induced apoptosis. 
3.5 MK2206 effectively enhanced CDDP-induced cytotoxicity in 
mouse in vivo model 
For the clinical use of MK2206 for urothelial carcinoma, we examined 
the effects of MK2206 alone or in combination with CDDP to the in vivo 
growth of RT112 cells, using a subcutaneous xenograft model. CDDP and 
MK2206 were given weekly, respectively. Significant body weight 
change in the mice could not be observed and the treatment was well 
tolerated. In our conditions, CDDP or MK2206 partially delayed tumor 
growth and the combination therapy suppressed tumor growth (Fig. 5A). 
The tendency of tumor growth inhibition was observed among groups, 
but there were no statistical differences among groups (P >0.05). Ki-67 
immunostaining of tumors demonstrated that combination treatment of 
MK2206 and CDDP could reduce tumor cells proliferation, compared 
with CDDP treatment alone. These results suggested that MK2206 could 
enhance CDDP-induced cytotocixity in vivo as well as in vitro. 
 
4. Discussion 
In the present study, we demonstrated that MK2206, one kind of Akt 
inhibitor, specifically enhanced the CDDP-induced cytotoxicity and 
apoptosis with the suppression of Akt pathway in urothelial cancer cell 
lines. The Akt pathway has been emphasized for the oncogenesis of many 
kinds of malignancy. We showed that MK2206 sensitized these cancer 
cells to CDDP via the inhibition of phosphorylation of Akt and its 
downstream molecules in Akt pathway. These results indicated that Akt 
pathway is a novel candidate to influence chemosensitivity to CDDP in 
urothelial cancers. 
Overactivation of Akt can influence many downstream effectors and 
mediate multiple pathways that favour tumourigenesis and as such it is 
one of the most frequently hyperactivated protein kinases in human 
cancer [23]. Akt, as one of the important target in phosphatidylinositol-3 
kinase (PI3K)/Akt signaling pathway, has three isoforms: Akt1, Akt2 and 
Akt3 [2,24]. The Akt pathway can be activated by numerous growth 
factors, mitogens, hormones and nutrients. Meanwhile, it can also be 
activated by the disruption of negative feedback mechanisms. The 
phosphatase and tensin homologue (PTEN), as a tumor suppressor, 
negatively regulates the Akt pathway by hydrolysing phosphatidylinositol 
triphosphate (PIP3) to phosphatidylinositol biphosphate (PIP2). Loss of 
PTEN strongly correlates with the activation of Akt in tumour cell lines, 
and recent studies have shown that reduced PTEN expression is common 
in UC [25,26]. The activation of Akt signaling pathway correlates with 
tumor progression and reduced survival in urothelial cancer. The high 
expression of p-Akt corresponded significantly with high-grade, 
advanced-stage and a higher risk of mortality in patients with urothelial 
cancer [10]. 
MK2206，a highly selective allosteric inhibitor of Akt, is being tested 
in both preclinical settings and clinical trials as an anticancer agent. 
MK2206 by itself causes cell proliferation inhibition of cell lines, 
including non-small-cell lung cancer lines, hepatocellular cancer lines, 
breast cancer lines, nasopharyngeal carcinoma cell lines and so on 
[17-19,27]. MK2206 also could synergistically enhance antitumor 
efficacy with some chemotherapeutic drugs. Meanwhile, cell invasion can 
be inhibited when treated with MK2206 in glioma cell lines, and cell 
invasion suppression coincided with decreased Akt phosphorylation [28]. 
In our study, MK2206 (500 nM) alone suppressed Akt phosphorylation 
effectively using the concentration which could inhibit cell proliferation 
modestly in urothelial cancer cell lines. Further, it has been shown that 
cell invasion rate was suppressed significantly by MK2206 (500 nM), 
with the inhibition of Snail and ZEB1 which were transcription factors 
related with epithelial to mesenchymal transition (EMT). In addition, our 
study showed that the result of invasion assay was influenced by 
decreased cell proliferation. Cell proliferation was suppressed about 20% 
by MK2206 at 500nM, which was the same dose in invasion assay. So if 
normalized, the decrease in cell invasion rate would be roughly 30%. It 
has been reported that Snail and ZEB1 expression were associated with 
invasion, metastasis and decreased chemosensitivity in some tumors, and 
inhibition of those targets increased the chemosensitivity [29-31]. Our 
results may indicate that suppressed Akt phosphorylation played a role in 
the inhibition of cell invasion and repression of Snail and ZEB1. 
To investigate the possible role of Akt in the CDDP-induced 
cytotocixitiy, we examined the impact of cell proliferation in urothelial 
cancer cell lines. Invasive cell lines were increasingly resistant to CDDP 
than noninvasive cell lines, and combination use of CDDP and MK2206 
clearly inhibited cell proliferation in comparison with single use of CDDP. 
Previous data has suggested that Akt regulated CDDP sensitivity in 
human lung cancer and ovarian cancer [15,16]. Therefore, Akt inhibition 
is suspected to have a mechanism to promote CDDP susceptibility. We 
found the contribution of Akt pathway inhibition to apoptosis using 
MK2206, by showing the enhancement of CDDP-induced apoptosis in 
CDDP plus MK2206. Conformational change of survivin by MK2206 has 
been reported to cause survivin suppression [19]. Our result showed that 
the change of survivin protein may mediate apoptosis through blockade 
of Akt pathway. These findings suggest that MK2206 might inhibit the 
activation of Akt pathway, leading to acceleration of CDDP-induced 
apoptosis. Here, we showed that the combination therapy may be 
effective to overcome the pre-existing resistance to chemotherapeutic 
drug of bladder cancer, that is, promotion of chemosensitivity. But 
another important subject of chemotherapy against bladder cancer is 
chemoresistance acquired during the chemotherapy, that is, treatment 
refractory. To examine the effectiveness of this combination therapy 
against chemoresistance, we need further experiments using 
CDDP-resistant cell lines in the future. If this treatment is also effective 
against chemoresistant situation, indication of this combination therapy 
would be further expanded. 
In this study, we also demonstrated that 4EBP1 and mTOR seem to act 
as the downstream targets of Akt pathway to promote apoptosis. 
Generally, p-4EBP1 and p-mTOR have a close relation to protein 
synthesis, and the activation of p-4EBP1 and p-mTOR has been reported 
to increase in the regulation of tumor growth [32]. Previous findings have 
suggested that cell cycle arrest, apoptosis, and autophagy were induced in 
T-ALL cells through inhibiting Akt/mTOR/4EBP1 [33]. Piperlongumine 
induce caspase-dependent apoptosis in human breast cancer cells via the 
inhibition of p-Akt, p-70S6K, p-4EBP1 [34]. From our data, considerable 
apoptosis was detected in combination use of CDDP and MK2206, 
depending on the suppression of Akt signaling pathway including 
reduction of p-4EBP1 and p-mTOR. Interestingly, our results showed that 
CDDP-induced Akt activation was observed significantly in RT112, not 
in T24. Whereas combined treatment of CDDP and MK2206 inhibited 
CDDP-induced activation of Akt, 4EBP1 and mTOR in both of cell lines. 
To assess the clinical usefulness and safety, we used a subcutaneous 
xenograft tumor model. In this model, MK2206 was administered by 
intraperitoneally at 50 mg/kg once per week. This dose was lower than 
those reported previously [19], which used the dose of 100 mg/kg once 
per week, but this low concentration could still enhance cancer-specific 
CDDP-induced cytotoxicity and significant tendency of tumor growth 
inhibition was found in combination therapy group. However, statistical 
differences could not be observed among groups. When we consider 
clinical application of MK2206 at a low concentration with 
chemotherapeutic agents, a combination with CDDP, which is one of the 




In the current study, we demonstrated that MK2206 could promote 
CDDP-induced cytotoxicity and apoptosis in urothelial cancer cells by 
the suppression of Akt activation and its downstream targets. Akt target 
therapy using MK2206 will develop as a promising strategy applied to 
enhance chemosensitivity to CDDP in urothelial cancers.  
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Figure legends 
Figure 1  Expression status of the Akt signaling pathway in urothelial 
cancer cell lines. Western blot shows the expression of Akt and its 
downstream targets in noninvasive and invasive urothelial cancer cell 
lines.  
 
Figure 2  The effect of MK2206 treatment on phospho-Akt expression, 
cell proliferation, and cell invasion in urothelial cancer cell lines. A, cell 
lines were exposed to MK2206 at indicated dose for 24h, and the 
expression of p-Akt was examined with Western blot. B, cell viability 
curves after treatment with MK2206 as in A. Mean values from at least 
three independent experiments are shown; bars represent S.D. C-D, 
invasive capability of UMUC3 was evaluated by transwell invasion assay. 
The cell suspension (5×104 cells) and reagents (DMSO or MK2206) were 
added to the insert of a transwell cell culture chamber, incubated for 24h 
with medium containing 10% FBS in the bottom of the chamber. The 
cells that attached to the lower side of the membrane were fixed with 70% 
ethanol and stained with hematoxylin. Each experiment was triplicate and 
the average number of cells in five microscopic fields (×200) was defined 
as the number of invasive cells. Representative microscopic image (C) 
and quantitated cell numbers (mean ± S.D.) of three independent 
experiments (D) were shown. E, UMUC3 cells were treated with control 
(DMSO) or MK2206 (500 nM) for 24h and abundance of indicated 
proteins were examined using Western blot. 
 
Figure 3  Effect of combinatorial treatment with MK2206 and CDDP in 
urothelial cancer cell lines. A, cell viability was evaluated 24h after 
CDDP treatment at indicated concentrations using MTT assay among six   
urothelial cancer cell lines. B, MTT assay showing effect of CDDP 
treatment with or without MK2206 (500 nM) in indicated urothelial cell 
lines. Average values from at least three independent experiments are 
shown; bars represent S.D. 
 
Figure 4  Influence of combined MK2206 treatment on CDDP-induced 
apoptosis in urothelial cancer cell lines. A.1, cells were exposed with 
MK2206 (500nM) alone for the indicated times. A.2, cells were treated 
with CDDP at the concentration corresponding to IC30 (300 µM) with or 
without treatment of 500 nM MK2206 for the indicated times and the 
abundance of indicated protein was examined using Western blot. ‘0h’ 
refers to the time for addition of reagents. B-C, cells were harvested after 
treatment with or without CDDP at indicated doses corresponding IC30 
for each cell line in the presence or absence of 500 nM MK2206 for 12h.  
 
Figure 5  Effect of combinatorial treatment with CDDP and MK2206 on 
the growth of RT112 subcutaneous xenograft tumor in vivo. A, the change 
of subcutaneous RT112 tumor volume measured using the Vernier Caliper. 
After tumors reached indicated volume, tumor-bearing mice were treated 
with indicated drugs as shown in the figure and described in ‘Materials 
and methods’, and the effect of indicated drugs on tumor growth was 
measured by the Vernier Caliper. B, histological examination of the effect 
of CDDP and MK2206 on RT112 tumor in vivo. At day 15, the mice were 
killed, and the tumors were dissected. Expression of Ki-67 was assessed 
by immunohistochemistry. Percentage of Ki-67 positive cells in each 
treatment group were compared (*, P < 0.05 vs control; **, P < 0.05, 
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